Which population is most likely to benefit from the herpes zoster vaccine?

The herpes zoster vaccine, commonly known as the shingles vaccine, is primarily recommended for older adults, specifically those over the age of 50. This population is at a significantly increased risk for developing herpes zoster due to a decline in immunity to the varicella zoster virus as people age. The likelihood of experiencing severe complications, such as postherpetic neuralgia, also increases with age, making vaccination particularly beneficial for this demographic.

While children under 12 typically have a robust immune response and are less likely to experience severe illness from the varicella virus, they are not the primary target for the shingles vaccine. Pregnant women are generally advised against receiving live vaccines, including the herpes zoster vaccine, during pregnancy due to potential risks to the fetus. Immunocompromised patients, depending on their specific condition and treatment regimen, may have restrictions on receiving live vaccines as well, which could include the herpes zoster vaccine.

Therefore, adults over 50 are the group most likely to benefit from vaccination against herpes zoster, as they can help reduce the incidence and severity of shingles and its complications.